Neurogene Maps NGN-401 Pivotal Rett Timeline, Mid-2026 Data Update at Guggenheim Summit

Neurogene Maps NGN-401 Pivotal Rett Timeline, Mid-2026 Data Update at Guggenheim Summit

Neurogene (NASDAQ:NGNE) is advancing a genetic medicines pipeline focused on rare neurologic diseases, with its lead program NGN-401 aimed at treating Rett syndrome, President and CFO Christine Mikail said at Guggenheim’s 2026 Emerging Outlook Biotech Summit. Mikail described Rett syndrome as a “de

Entrada Therapeutics Teases Data-Rich 2026 With DMD and DM1 Catalysts at Guggenheim Summit

Entrada Therapeutics (NASDAQ:TRDA) used a presentation at Guggenheim’s 2026 Emerging Outlook Biotech Summit to outline its pipeline focus on intracellular therapeutics and to preview multiple clinical data catalysts expected in 2026, particularly in Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). Company focus and platform CEO Dipal Doshi described Entrada as a Boston-based […]